$14.26
+0.73 (+5.40%)
CSIQ News6 articles
Xero Data Reveals U.S. Small Business Sales Slowdown, Canadian Contraction
Xero's latest data shows U.S. small business sales growth decelerated sharply to 0.9% year-over-year in the December quarter, with Canadian sales contracting 4.1%. The company cited tariff impacts and policy uncertainty.
Denison Mines Secures Key Canadian Approval for Phoenix Uranium Mine
Denison Mines Corp. shares advanced in premarket trading following Canadian regulatory approval for construction of its flagship Phoenix uranium mine. The decision shifts focus to the company's final investment decision and construction timeline.
Paladin Energy Gains on Key Canadian Uranium Project Approval
Paladin Energy Ltd. advanced after receiving provincial environmental sign-off for its Patterson Lake South uranium project in Canada. The approval marks a key regulatory milestone as the company progresses toward federal licensing.
Air Transat Launches Direct Rio Flights Amid Canadian Airline Route Expansion
Air Transat initiates nonstop Toronto/Montreal-Rio de Janeiro service, becoming the sole carrier on the Montreal route. The move coincides with a broader February route rollout by Canadian and international airlines.
Novartis Advances with Canadian Reimbursement and Major U.S. R&D Expansion
Novartis shares gained as the company secured a draft reimbursement nod in Canada for Kisqali and broke ground on a $23 billion U.S. research center. Investors eye upcoming dividend and annual meeting.
Merck Shares Approach 52-Week High on Canadian RSV Drug Approval
Merck stock gained 1.8% after Health Canada approved its ENFLONSIA RSV antibody for infants. Guggenheim raised its price target to $140, while insider sales were disclosed.